Amlodipine (As Besylate) With Valsartan And Hydrochlorothiazide
Recommended CardiovascularRestricted
Hypertension in a patient who is not adequately controlled with any two of the drugs in the combination.
1
Submissions
2010–10
On the record
—
ICER range
Cost-min
Cost basis
Decisions on record
- Meeting Nov 2011 Recommended High blood pressure no PSD
- Meeting Jul 2010 Recommended Antihypertensive
Access path
- Jul 2010Recommended · restricted
vs amlodipine, valsartan and hydrochlorothiazide given…
- PBS listing · Restricted
RecommendedDeferredNot recommended
Cost-effectiveness
Cost-minimisation analysis conducted; no ICER calculated
The PBAC noted that the listing would allow add-on as well as substitution therapy but considered that this was consistent with current guidelines and clinical practice for the treatment of hypertension. It is also consistent with recommendations made by the PBAC at the March 2010 meeting regarding the ACEI/ATRA with diuretic combination products and the ACEI/ATRA with calcium channel blocker and is a pragmatic approach PBAC · 2010
Cost-effectiveness accepted
Decision context
Populationpatients who are not adequately controlled with any two of the drugs in the combination (amlodipine, valsartan and hydrochlorothiazide)
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Jul 2010 | Recommended · restricted | amlodipine, valsartan and hydrochlorothiazide given concomitantly (three component products) | — | RCT · BP control rates |
Similar precedents
Amlodipine Besylate With Valsartan93%Valsartan With Hydrochlorothiazide79%Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide80%Perindopril Arginine With Amlodipine Besylate78%Olmesartan Medoxomil With Amlodipine77%Telmisartan With Amlodipine76%Olmesartan Medoxomil With Hydrochlorothiazide76%Ramipril With Felodipine72%